Most of the excess expenditure in the US is not going to pharma and other device companies for research; it is instead being divided up by billing companies working for hospitals, doctors and other businesses in the supply chain.
This should be obvious to anyone who looks at the charts and sees the mean cost vs the high and low end: companies are charging what they can when they can to the end user because there is no good advocate for the end user and they are up against a wall.
I also expand on who does in effect pay for medics research and the answer is not the American consumer but mostly the taxpayers (and philanthropists to university endowments etc) of the world given that most of the research that advances medical knowledge, that is innovative rather than iterative research, is performed in universities.
Too much effort: didn't read?
The summly version:
Most of the excess expenditure in the US is not going to pharma and other device companies for research; it is instead being divided up by billing companies working for hospitals, doctors and other businesses in the supply chain.
This should be obvious to anyone who looks at the charts and sees the mean cost vs the high and low end: companies are charging what they can when they can to the end user because there is no good advocate for the end user and they are up against a wall.
I also expand on who does in effect pay for medics research and the answer is not the American consumer but mostly the taxpayers (and philanthropists to university endowments etc) of the world given that most of the research that advances medical knowledge, that is innovative rather than iterative research, is performed in universities.